Pharmacokinetic interaction between levofloxacin and ciclosporin or tacrolimus in kidney transplant recipients: Ciclosporin, tacrolimus and levofloxacin in renal transplantation

Clinical Pharmacokinetics

Volumn 45, Issue 2, 2006, Pages 169-175

  Federico, Stefano ^a,b   Carrano, Rosa ^a   Capone, Domenico ^a   Gentile, Antonio ^a   Palmiero, Giuseppe ^a   Basile, Vincenzo ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; IMMUNOSUPPRESSIVE AGENT; LEVOFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TSUKUBAENOLIDE;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG EXCRETION; DRUG METABOLISM; FEMALE; GRAM NEGATIVE AEROBIC RODS AND COCCI; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LIVER METABOLISM; MALE; MICROEMULSION; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; URINARY TRACT INFECTION;

ADULT; ANTI-BACTERIAL AGENTS; AREA UNDER CURVE; CLINICAL TRIALS; CYCLOSPORINE; DRUG INTERACTIONS; FEMALE; GRAFT REJECTION; HALF-LIFE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; OFLOXACIN; TACROLIMUS; TRANSPLANTATION IMMUNOLOGY;

EID: 33344471694     PISSN: 03125963     EISSN: 03125963     Source Type: Journal    
DOI: 10.2165/00003088-200645020-00003     Document Type: Article

References (29)

1. Davis R, Bryson HM. Levofloxacin: a review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 1994 Apr; 47 (4): 677-700
2. Kronbach T, Fischer V, Meyer UA. Cyclosporine metabolism in human liver: identification of a cytochrome P450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs. Clin Pharmacol Ther 1988 Jun; 43 (6): 630-5
3. Shiraga T, Matsuda H, Nagase K, et al. Metabolism of FK506, a potent immunosuppressive agent, by cytochrome P450 3A enzymes in rat, dog and human liver microsomes. Biochem Pharmacol 1994 Feb; 47 (4): 727-35
4. Christians U, Sewing KF. Cyclosporin metabolism in transplanted patients. Pharmacol Ther 1993 Feb-Mar; 57 (2-3): 291-345
5. Dambrin C, Klupp J, Morris RE. Pharmacodynamics of immunosuppressive drugs. Curr Opin Immunol 2000 Oct; 12 (5): 557-62
6. Matsuda H, Iwasaki K, Shiraga T, et al. Interactions of FK506 (tacrolimus) with clinically important drugs. Drug Metab Dispos 1992; 20 (5): 753-61
7. McLellan RA, Drobitch RK, McLellan H, et al. Norfloxacine interferes with cyclosporine disposition in pediatric patients undergoing renal transplantation. Clin Pharmacol Ther 1995 Sep; 58 (3): 322-7
8. Elston RA, Taylor J. Possible interaction of ciprofloxacin with cyclosporine. J Antimicrob Chemother 1988 May; 21 (5): 679-80
9. Nasir M, Rotellar C, Hand M, et al. Interaction between ciprofloxacin and cyclosporine. Nephron 1991; 57 (2): 245-6
10. McLellan RA, Drobitch RK, Monshouwer M, et al. Fluoroquinolone antibiotics inhibit cytochrome P450-mediated microsomal drug metabolism in rat and human. Drug Metab Dispos 1996 Oct; 24 (10): 1134-8
11. Neuman M. Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet 1988 Feb; 14 (2): 96-121
12. Outman WR, Nightingale CH. Metabolism and the fluoroquinolones. Am J Med 1989 Dec; 87 Suppl. 6C: 37-42S
13. Doose DR, Walker SA, Chien SC, et al. Levofloxacin does not alter cyclosporine disposition. J Clin Pharmacol 1998 Jan; 38 (1): 90-3
14. Levy G, Grant D. Potential for CsA-Neoral in organ transplantation. Transplantation Proc 1994 Oct; 26 (5): 2932-4
15. Annesley TM, Hunter BC, Fidler DR, et al. Stability of tacrolimus (FK 506) and cyclosporine G in whole blood. Ther Drug Monit 1995 Aug; 17 (4): 361-5
16. De Wildt SN, Kearns GL, Leeder JS, et al. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet 1999 Dec; 37 (6): 485-505
17. Lemahieu WPD, Maes BD, Verbeke K, et al. Impact of gastric acid suppressants on cytochrome P450 3A4 and P-glycoprotein: consequences for FK506 assimilation. Kidney Int 2005; 67: 1152-60
18. Cummins CL, Wu CY, Benet LZ. Sex-related differences in the clearance of cytochrome P450 3A4 substrates may be caused by P-glycoprotein. Clin Pharmacol Ther 2002 Nov; 72 (5): 474-89
19. Seifeldin R. Drug interaction in transplantation. Clin Ther 1995 Nov-Dec; 17 (6): 1043-61
20. Christians U, Jacobsen W, Benet LZ, et al. Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 2002; 41 (11): 813-51
21. Capone D, Aiello C, Santoro GA, et al. Drug interaction between cyclosporine and two antimicrobial agents, josamycin and rifampicin, in organ transplanted patients. Int J Clin Pharm Res 1996; 16 (2-3): 73-6
22. Capone D, Gentile A, Imperatore P, et al. Effects of itraconazole on tacrolimus blood concentrations in a renal transplant recipient. Ann Pharmacother 1999 Oct; 33 (10): 1124-5
23. Borner K, Lode H. Biotransformation of certain gyrase inhibitors. Infection 1986; 14 Suppl. 1: S54-9
24. Kivisto KT. A review of assay methods for cyclosporine: clinical implications. Clin Pharmacokinet 1992 Sep; 23 (3): 173-90
25. Capone D, De Marino V, Caso N, et al. Polyclonal/monoclonal ratio in kidney and bone marrow transplanted patients treated with cyclosporine. Clin Transplant 1998 Oct; 12 (5): 430-3
26. Capone D, De Marino V, Fontana R, et al. Effects of different routes of cyclosporin A administration on blood levels in patients undergoing bone marrow transplantation. Bone Marrow Transplant 1997 Feb; 19 (4): 369-72
27. Browne BJ, Holt CO, Emovon OE. Diurnal cyclosporine dosing optimizes exposure and reduces the risk of acute rejection after kidney transplantation. Clin Transplant 2001; 15 Suppl. 6: 51-4
28. Choi JS, Park HJ. Circadian changes in pharmacokinetics of cyclosporine in healthy volunteers. Res Commun Mol Pathol Pharmacol 1999 Jan; 103 (1): 109-12
29. Milanian I, Ghods AJ, Mahmoudian M, et al. Study of circadian variation of cyclosporine pharmacokinetics. Transplantation Proc 1997 Nov; 29 (7): 2930-1